[A19-03] Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51

Last updated 21.03.2019

Project no.:
A19-03

Commission:
Commission awarded on 07.01.2019 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Indication:

Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy

Result of dossier assessment:

Now hint of minor added benefit after pretreatment with a conventional synthetic DMARD. Added benefit still not proven after pretreatment with a biological DMARD

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2019-02-21 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form